Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 186 participants.

Also called NCT03377335

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 186 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03377335
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03377335. Randomized; no masking; primary purpose treatment. Start 2017-12-22 (actual); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Dapagliflozin 10mg
Intervention (Drug)
Metformin
Lead sponsor
University of Palermo (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
University of Catania (class: other)

Record details

Record id
cardio:ct-nct03377335
Content hash
93c9cfa30660ce381960d4aefa59473c178befcb71059669465ea258d6792650